GSK teams up with US researchers in bid to 'cure HIV'
This article was originally published in Scrip
GlaxoSmithKline is to invest $4m a year for five years to fund a new HIV research center focused on discovering a cure for HIV/AIDS at the University of North Carolina at Chapel Hill, and a jointly owned new company called Qura Therapeutics which will handle the business side of the partnership.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.